Top drugs chase bigger markets

Some big names are seeking a greater population to treat at the July PBAC meeting, as PBAC gets set to consider 14 changes to listings.

BMS is seeking another couple of indications for Opdivo and Yervoy. One is for the first line treatment of microsatellite instability high or mismatch repair deficient unresectable or metastatic colorectal cancer. The other is for the first line treatment of advanced unresectable Barcelona Clinic Liver Cancer Stage A, Stage B or Stage C hepatocellular carcinoma.

Ipsen has submitted Cabometyx for another indication, the treatment of unresectable locally advanced or metastatic well- or moderately-differentiated pancreatic neuroendocrine tumors or extra-pancreatic neuroendocrine tumors.